Approved for use through 07/31/2512\_OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paparwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMS control number

			SI	ATEMENT UNDER 3	CFR 3.73(b)
Applic	ant/f	Patent Own	er: James Say		
Application No./Patent No.: 90/009.763					led/issue Date: 06/18/2010
Titled			CHEMICAL ANALYTE		
Abbot	t Dia	abetes Ca	re Inc.	. a corporation	
(Name of Assignee)				(Type of Assi	gnee, e.g., corporation, partnership, university, government agency. etc.
states	that	it is:			
1. [	X	the assign	ee of the entire right, title, a	ind interest in:	
2		an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or			
3. [		the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)			
the pa	atent	application	/patent identified above, by	virtue of either;	
A [		An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy therefore is attached.			
OR					and the second and the second and fallows.
В.	ΧI	A chain of			atent identified above, to the current assignee as follows:
		1. From:	The document was recorde	ed in the United States Pa	To: E. Heller & Company  tent and Trademark Office at  or for which a copy thereof is attached.
		2, From	E. Heller & Company		To: Therasense, Inc.
				ed in the United States Pa	stent and Trademark Office at or for which a copy thereof is attached.
		3. From:	Therasense, Inc.		To: Abbott Diabetes Care Inc.
			The document was records	ed in the United States Pa	stent and Trademark Office at
			Reel 026104	. Frame 0413	or for which a copy thereof is attached.
		Addition	al documents in the chain of	title are listed on a supp	emental sheet(s).
$\boxtimes$	or c	concurrently	is being, submitted far rec	ordation pursuant to 37 (	
	(NC	OTE: A sep cordance w	arafe copy (i.e., a true copy th 37 CFR Part 3, to record	of the original assignment in the re	ent document(s)) must be submitted to Assignment Division in cords of the USPTO. <u>See</u> MPEP 302.08]
The u	inder	signed (wh	ose title is supplied below)	s authorized to act on be	half of the assignee.
			37 6		27-2-2-2-1
Signature					Date
Susan C. Tall					Senior Counsel
	P	rinted or Ty	ped Name		Title

This collection of information is required by \$7 CFR 3 73(b). The information is required to extend or retain a headility by the golder which is to fine (and by the USPTO to process) an application. Considerability is governed by \$5 U SC 1/22 and \$7 CFR 1,11 and 1,14. This collection is estimated to take 12 minusible to complete, including pattering, preparent, and submitting the considered application form to the USPTC. The well very depending upon the inclinical case. Any comments on the amount of leves you require to complete this form another suggestions for reducing boulder, should be earth to the Charli formation foreign. U.S. Patterl and Trademank, Office, U.S. Department of Comments, or Place 1 and Trademank of Comments or the comments of the comme for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

Attorney Docket No. 031312-01174

Title:

ELECTROCHEMICAL ANALYTE SENSOR

Use Space Below for Additional Information:

Statement Under 37 CFR 3.73(b) continued

Additional Documents in Chain of Title

Ratification of Assignments By: Therasense Inc. Execution Date: December 13, 2000 Reel/Frame: 011682/0736

Change of Name: From: Therasense Inc. To: Abbott Diabetes Care, Inc. Executed: July 25, 2005, a copy thereof is attached